The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

BCR-ABL tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia, inducing deep molecular responses, largely improving patient survival and rendering treatment-free remission possible. However, three of the five BCR-ABL TKIs, dasatinib, nilotinib, and ponatinib, inc...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Pharmacol
Hlavní autoři: Haguet, Hélène, Bouvy, Céline, Delvigne, Anne-Sophie, Modaffari, Elise, Wannez, Adeline, Sonveaux, Pierre, Dogné, Jean-Michel, Douxfils, Jonathan
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2020
Témata:
Pharmacology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7350860/
https://ncbi.nlm.nih.gov/pubmed/32719607
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.01007
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky